Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DST-2970 in Prostate Cancer with Rising PSA on Abiraterone
NCT04291664Phase 1Terminated
- Sponsor
- DisperSol Technologies
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 1, open-label trial in prostate cancer (PCa) (3 arms), sponsored by DisperSol Technologies. Primary endpoints: Maximum-tolerated dose, Recommended Phase II dose and 1 more. Started Jan 2020; status: terminated.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04291664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291664.